Furthermore, to selectively transfer the BLZ945, a (Colony-Stimulating Factor 1 Receptor) CSF-1R inhibitor, in a targeted approach via repolarization of the tumor immune milieu, Sharma et al. produced a unique hydroxyl dendrimer-mediated immunotherapy. This evidence concerns the gene CSF1R and neoplasm.